8.66

5.10% 0.42

Pre-market: 8.66

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $8.66, with a volume of 800.60K. It is up +5.10% in the last 24 hours and up +7.31% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Previous Close:

$8.24

Open:

$8.29

24h Volume:

800.60K

Relative Volume:

0.86

Market Cap:

$447.24M

Revenue:

$742.90M

Net Income/Loss:

$52.60M

P/E Ratio:

10.44

EPS:

0.8295

Net Cash Flow:

$156.80M

1W Performance:

+10.32%

1M Performance:

+7.31%

6M Performance:

-4.73%

1Y Performance:

+89.08%

1-Day Range:

$8.29

$8.84

1-Week Range:

$7.85

$8.84

52-Week Range:

$4.44

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2025-03-03

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	8.66	411.09M	742.90M	52.60M	156.80M	0.8295
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Apr 14, 2026

Emergent BioSolutions (EBS) price target decreased by 11.11% to 12.24 - MSN

Apr 14, 2026

Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Apr 14, 2026

Apr 13, 2026

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness - Bioscience Association Manitoba

Apr 13, 2026

Apr 12, 2026

Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com

Apr 12, 2026

Apr 11, 2026

Emergent BioSolutions Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 11, 2026

Apr 10, 2026

Emergent Biosolutions partners with British Columbia to supply NARCAN nasal spray for expanded program - Traders Union

Apr 10, 2026

Apr 09, 2026

Earnings Risk: Is Emergent BioSolutions Inc stock showing strong momentum2026 Earnings Impact & Capital Efficient Trading Techniques - baoquankhu1.vn

Apr 09, 2026

Emergent Biosolutions Partners With British Columbia To Supply Narcan® Nasal Spray For The Launch Of The Expanded Bc Take Home Naloxone Program - TradingView — Track All Markets

Apr 09, 2026

Emergent BioSolutions (EBS) Partners with B.C. for Nasal Naloxone Expansion - GuruFocus

Apr 09, 2026

B.C. puts $18M into nasal naloxone, taps Emergent for NARCAN - Stock Titan

Apr 09, 2026

Dimensional Fund Advisors (EBS) reports 2.76M shares, 5.3% stake - Stock Titan

Apr 09, 2026

Apr 08, 2026

Aug Fed Impact: How does Emergent BioSolutions Inc perform in inflationary periods2026 Big Picture & Advanced Technical Analysis Signals - baoquankhu1.vn

Apr 08, 2026